Engineered immune cells take on deadly brain tumors in new trial
NCT ID NCT07318818
First seen Jan 07, 2026 · Last updated Apr 28, 2026 · Updated 21 times
Summary
This study tests a new treatment called P134 cells, which are specially engineered immune cells (CAR-T cells) designed to target and attack recurrent glioblastoma, a severe type of brain cancer. The trial involves 26 adults whose cancer has returned and who have a specific marker on their tumor cells. The main goals are to check the treatment's safety, find the best dose, and see if it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital, Capital Medical University
RECRUITINGBeijing, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.